SAN ANTONIO--(BUSINESS WIRE)--Pfizer today announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free survival (BCFS) and censored deaths that occurred prior to breast cancer relapse. These data showed that women who switched to Aromasin® (exemestane tablets) after 2.5 years of tamoxifen experienced a 19 percent reduction in risk of breast cancer recurrence (BCFS) (HR=0.81 95% CI (0.71, 0.92); p<0.001) compared to women who continued on tamoxifen for a full five years of treatment. Separately, results from the Tamoxifen, Exemestane, Adjuvant, Multicenter (TEAM) study did not show a difference in disease free survival (DFS) in women who took Aromasin for five years compared to those who switched from tamoxifen to Aromasin after two to three years (HR=0.97 (95% CI 0.88-1.08); P=0.604). Data from IES and TEAM, presented today at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), continue to underscore the benefits of Aromasin for postmenopausal women with hormone-receptor positive/unknown early breast cancer.
